Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E31.33 EPS (ttm)1.90 Insider Own0.03% Shs Outstand2.88B Perf Week-1.80%
Market Cap171.69B Forward P/E16.60 EPS next Y3.59 Insider Trans4.59% Shs Float2.87B Perf Month2.01%
Income5.61B PEG7.78 EPS next Q0.88 Inst Own75.80% Short Float0.93% Perf Quarter3.24%
Sales43.55B P/S3.94 EPS this Y-26.50% Inst Trans-1.21% Short Ratio3.29 Perf Half Y7.38%
Book/sh16.58 P/B3.59 EPS next Y2.78% ROA5.40% Target Price61.94 Perf Year28.55%
Cash/sh4.64 P/C12.82 EPS next 5Y4.03% ROE11.50% 52W Range43.23 - 60.89 Perf YTD21.64%
Dividend1.76 P/FCF32.94 EPS past 5Y-16.50% ROI6.60% 52W High-2.25% Beta0.42
Dividend %2.96% Quick Ratio1.50 Sales past 5Y13.00% Gross Margin60.20% 52W Low37.69% ATR0.70
Employees77300 Current Ratio1.90 Sales Q/Q-0.70% Oper. Margin18.60% RSI (14)53.88 Volatility1.03% 1.14%
OptionableYes Debt/Eq0.48 EPS Q/Q126.70% Profit Margin12.90% Rel Volume0.95 Prev Close59.55
ShortableYes LT Debt/Eq0.38 EarningsJul 29 BMO Payout90.60% Avg Volume8.14M Price59.52
Recom2.50 SMA200.08% SMA502.30% SMA2008.47% Volume7,738,900 Change-0.05%
30-Apr-14Reiterated Argus Buy $62 → $66
11-Apr-14Reiterated MKM Partners Buy $64 → $70
05-Feb-14Reiterated Argus Buy $54 → $62
14-Jan-14Reiterated MKM Partners Buy $59 → $64
03-Jun-13Reiterated MKM Partners Buy $54 → $59
15-Apr-13Reiterated Barclays Overweight $45 → $60
04-Feb-13Reiterated MKM Partners Buy $51 → $52
04-Feb-13Reiterated Barclays Overweight $46 → $45
20-Nov-12Upgrade MKM Partners Neutral → Buy $47 → $51
17-Oct-12Reiterated MP Advisors Outperform $45 → $50
30-Jul-12Reiterated UBS Buy $45 → $50
13-Jul-12Upgrade MP Advisors Market Perform → Outperform $45
03-Feb-12Reiterated Barclays Capital Overweight $38 → $40
03-Feb-12Downgrade MKM Partners Buy → Neutral $42 → $40
29-Nov-11Initiated MKM Partners Buy $38
14-Sep-11Reiterated Barclays Capital Overweight $41 → $38
16-May-11Reiterated UBS Buy $40 → $42
04-Feb-11Reiterated UBS Buy $42 → $40
24-Jan-11Reiterated Deutsche Bank Buy $48 → $43
24-Jan-11Reiterated Barclays Capital Overweight $43 → $41
16-Sep-14 03:16AM  AstraZeneca gets up to $500 mln from Lilly for Alzheimer's drug Reuters
15-Sep-14 04:51PM  Merck osteoporosis drug passes trial, but side effects hover Reuters
02:42PM  Merck KGaA Stops All Tecemotide Studies for Lung Cancer Zacks
02:36PM  New Safety And Efficacy Data On Merck's Osteoporosis Drug, Odanacatib at Forbes
02:36PM  Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial at Forbes
02:33PM  Long-delayed Merck osteoporosis drug meets goal in study Reuters
01:56PM  Merck says osteoporosis drug achieves goal in large trial Reuters
01:30PM  Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis Business Wire
08:14AM  Merck's Mantra On Focus Precludes An Inversion Strategy at Forbes
12-Sep-14 04:07PM  Stocks close down ahead of Fed meeting; energy hit at CNBC
03:14PM  Stocks fall, on pace for first losing week in six; Fed eyed at CNBC
02:44PM  All S&P sectors drop; Dow falls 100 points at CNBC
01:29PM  Gilead Sciences: Sovaldi Sales Slip But Less Than Feared at Barrons.com
01:08PM  Stocks edge lower; all S&P sectors down at CNBC
12:03PM  Stocks decline on energy, utilities; Fed in focus at CNBC
11:32AM  Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies at TheStreet
11:24AM  $250 Billion in Biotech Drug Savings on Brink of Arrival at Bloomberg
08:04AM  Merck KGaA ends lung cancer vaccine trials Reuters
10-Sep-14 04:00PM  Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals Zacks
02:50PM  Is Merck & Co., Inc. A Leader In A Red Hot Market? Benzinga
11:00AM  Dow Component Merck (MRK) To Go Ex-dividend Tomorrow at TheStreet
09-Sep-14 04:00PM  TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant Zacks
01:21PM  3 picks to weather any coming correction Yahoo Finance
08-Sep-14 06:24PM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
05:00PM  Merck to Participate at the Morgan Stanley Global Healthcare Conference Business Wire
03:30PM  Bristol-Myers Sues Merck of Patent Infringement on Keytruda Zacks
11:11AM  [$$] A New Era in Immuno-Oncology at Barrons.com
10:18AM  Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug at The Wall Street Journal
09:50AM  Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug at The Wall Street Journal
01:11AM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
05-Sep-14 09:25PM  Bristol-Myers sues Merck over U.S. immunotherapy patent Reuters
04:04PM  Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug Benzinga
04:01PM  The 4 Stocks That Lifted the Market 24/7 Wall St.
03:01PM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
02:12PM  Bristol-Myers Sues Merck Over Cancer Immunotherapy Patent at Bloomberg
12:56PM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
10:20AM  Merck's Anti-PD-1 Drug Keytruda First to be Launched in US Zacks
09:48AM  [video] The Top Ten Stocks for Friday, September 5 at Bloomberg
09:42AM  Keytruda Cancer Drug Approval Is A Triumph For Merck: R&D Chief Roger Perlmutter On What's Next at Forbes
09:42AM  Cancer Drug Approval Is A Triumph For Merck: R&D Chief Roger Perlmutter On What's Next at Forbes
09:42AM  Cancer Drug Approval Is A Triumph For Merck. What's Next? at Forbes
09:03AM  El Pollo Loco shares go crazy again; Michael Kors stock sinks; Gap sales miss mark Hot Stock Minute
08:02AM  Jobs report; Gap tanks; Microsoft unveils 'selfie cam' Hot Stock Minute
08:02AM  Job growth slows; Gap tanks; Microsoft unveils 'selfie cam' Hot Stock Minute
07:41AM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
07:20AM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
02:09AM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
12:12AM  PRESS DIGEST- New York Times business news - Sept 5 Reuters
12:12AM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
04-Sep-14 10:48PM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
09:59PM  [$$] FDA Approves Merck's New-Wave Cancer Drug at The Wall Street Journal
06:33PM  U.S. approves Merck immune-stimulating drug for melanoma Reuters
06:12PM  [$$] Merck's Cancer Drug Approved at The Wall Street Journal
06:12PM  FDA Approves Merck's New-Wave Cancer Drug The Wall Street Journal
05:41PM  FDA OKs Merck drug, 1st in new cancer drug class AP
04:45PM  What This Skin Cancer Drug Approval Really Means To Merck at 24/7 Wall St.
04:45PM  What This Skin Cancer Drug Approval Really Means to Merck at 24/7 Wall St.
04:41PM  FDA OKs Merck drug for cancer at USA TODAY
04:40PM  F.D.A. Allows First Use Of a Novel Cancer Drug at New York Times
04:40PM  F.D.A. Allows First Use of a Novel Cancer Drug at New York Times
04:33PM  Merck PD-1 Inhibitor Approved For Skin Cancer at Investor's Business Daily
04:09PM  FDA OKs Merck drug, 1st in new cancer drug class AP
04:03PM  [$$] Merck's Cancer Drug Approved at The Wall Street Journal
04:03PM  Merck's Keytruda The Winner In U.S. PD-1 Inhibitor Race at Forbes
04:03PM  Merck's Keytruda The Surprise Winner In U.S. PD-1 Inhibitor Race at Forbes
04:03PM  Merck's Keytruda Surprise Winner In U.S. PD-1 Inhibitor Race at Forbes
04:03PM  FDA Approves Merck's PD-1 Inhibitor, Keytruda at Forbes
03:46PM  Merck Receives Accelerated Approval of KEYTRUDA┬« (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy PR Newswire
03:44PM  U.S. approves Merck immune-stimulating drug for melanoma Reuters
03:40PM  How Will Merck (MRK) Stock React To FDA Approval Of Melanoma Immunotherapy? at TheStreet
03:36PM  [$$] Merck's Cancer Drug Approved at The Wall Street Journal
03:25PM  [video] Accelerating Ebola vaccine at CNBC
03:15PM  Merck Receives Accelerated Approval of KEYTRUDA┬« (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy Business Wire
03:09PM  FDA OKs Merck drug, 1st in new cancer drug class AP
03:01PM  [$$] FDA Approves Merck's Cancer Drug at The Wall Street Journal
02:36PM  Merck Wins U.S. Approval for Melanoma Immunotherapy at Bloomberg
02:36PM  Merck Skin Cancer Immunotherapy Gets FDA Approval at TheStreet
02:30PM  Dow Today: Merck (MRK) Higher at TheStreet
09:50AM  [$$] Merck Bacterial Drug Fast-Tracked by FDA at The Wall Street Journal
09:00AM  Mercks Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA Business Wire
03-Sep-14 01:00AM  Sanofi Dengue Vaccine Works on All Four Types in Study at Bloomberg
02-Sep-14 03:30PM  Regeneron/Sanofi Presents Encouraging Alirocumab Data Zacks
02:34PM  Bad news in Hong Kong is good news for Singapore at CNBC
08:30AM  Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014 Business Wire
12:34AM  S.Korea lifts ban on beef with feed additive -food ministry Reuters
01-Sep-14 11:00PM  S.Korea lifts ban on beef with feed additive -food ministry Reuters
07:00PM  Identity Crisis in S&P 500 as Range of Valuations Narrows Bloomberg
28-Aug-14 11:20AM  Pharma Claims Free Speech Rights are Being Trampled in Off-Label Case at The Wall Street Journal
27-Aug-14 06:00PM  Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Zacks
01:11PM  [video] Options Insight: Unusual Activities on The Dow at Bloomberg
11:00AM  [video] Merck & Pfizer team up at CNBC
09:21AM  Will This Coverage Initiation Affect Merck (MRK) Stock Today? at TheStreet
09:17AM  UPDATE: Deutsche Bank Initiates Coverage On Merck Benzinga
26-Aug-14 06:45PM  Merck, Pfizer combining drugs Investor's Business Daily
06:24PM  Your first trade for Wednesday at CNBC
05:26PM  Cardiome Pharma Signs Agreement with Eurolab for Brinavess Zacks
04:18PM  Merck Is at the $60 Rubicon; Can It Cross This Time? at The Wall Street Journal
04:01PM  The 4 Stocks That Pushed the DJIA and S&P 500 to New Highs 24/7 Wall St.
03:34PM  [video] Why & what of the stock market at CNBC
03:14PM  Why Merck (MRK) Stock Is Gaining Today at TheStreet
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Option Exercise48.246,375307,53012,036Feb 14 05:11 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Sale55.475,990332,2766,046Feb 14 05:11 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Option Exercise36.5649,7501,818,86071,457Feb 14 11:17 AM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Sale55.0443,8702,414,57027,587Feb 14 11:17 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Option Exercise48.2410,000482,40020,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Option Exercise48.2445,0002,170,800304,349Feb 11 05:34 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Option Exercise47.6518,000857,70518,000Feb 13 10:12 AM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Sale55.6118,0001,000,9350Feb 13 10:12 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Sale55.7010,000557,00210,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Sale54.5241,5202,263,683262,829Feb 11 05:34 PM
WENDELL PETER CDirectorFeb 10Option Exercise47.235,000236,1506,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Option Exercise47.235,000236,1505,100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Option Exercise48.2420,000964,800156,049Feb 11 03:54 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Sale54.6850,0002,734,155106,049Feb 11 03:54 PM
WENDELL PETER CDirectorFeb 10Sale54.445,000272,1931,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Sale54.265,000271,283100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDJan 27Option Exercise47.7930,0001,433,700136,049Jan 28 10:09 AM